VIYASH Viyash Scientific Q4 FY25 results (Jan–Mar 2025) and concall
Viyash delivered strong Q4 and FY25 results, marked by significant revenue and EBITDA growth, robust free cash flow, and reduced debt. SeQuent Scientific also reported healthy growth and margin expansion. The merger process is advancing, with management highlighting substantial synergy potential, particularly in CDMO expansion and new product development, despite a minor sequential revenue dip for Viyash due to inventory phasing.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 42 | 338 | 42 |
| EBITDA | -2 | 58 | -3 |
| Net profit | 4 | 51 | 4 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
